. Analytical HPLC chromatograms and MALDI-TOF-MS spectra of purified synthetic proteins 3, 4, 5, and 7. HPLC experiments were performed on a C18 stationary phase (10 µm particle, 300 Å pore size) with indicated elution gradients (solvent A = 0.1 % TFA in water, solvent B = 0.1% TFA in acetonitrile).
Figure S2.
Analytical HPLC chromatograms and MALDI-TOF-MS spectra of purified synthetic proteins 8 and 9. HPLC experiments were performed on a C18 stationary phase (10 µm particle, 300 Å pore size) with indicated elution gradients (solvent A = 0.1 % TFA in water, solvent B = 0.1% TFA in acetonitrile). Additional analysis of protein 8 by gel permeation chromatography (GPC, isocratic elution in PBS on a Superdex 75 10/100 column) indicates the truncation product visible in the MALDI spectrum is a minor component of the sample. Figure S3 . Analytical HPLC chromatograms and MALDI-TOF-MS spectra of purified expressed proteins WT and K31A. HPLC experiments were performed on a C18 stationary phase (10 µm particle, 300 Å pore size) with indicated elution gradients (solvent A = 0.1 % TFA in water, solvent B = 0.1% TFA in acetonitrile). Figure S4 . CD data at 220 nm for proteins 3, 4, 5, 7, and 8 as a function of temperature and chemical denaturant concentration. Raw data (points) are fit (surface) to extract thermodynamic parameters for the folding equilibrium. Data for proteins 1, 2 and 6 were published previously. 1 Figure S5 . Packing interactions involving α-Lys 31 from the crystal structure of wild-type GB1 (A) and β 3 -Lys 31 from the crystal structure of 2 (B) show a salt bridge to Glu 27 and hydrophobic contact with Trp 43 . A model incorporating a β 3 -Lys 31 →β 2 -Ala mutation in 2 (C) shows how the side chain would project away from the two interaction partners after the substitution.
Figure S6
. Sequences and coupled thermal / chemical denaturation CD data for wild-type GB1 (WT) and Lys 31 →Ala mutant (K31A). Analysis of folding thermodynamics for these two proteins (Table S3 ) supports the energetic importance of side-chain contacts involving Lys 31 . Figure S7 . CD thermal melt of protein 9 at ~8 µM in 20 mM phosphate buffer pH 7. The concentration was difficult to measure accurately due to the low yield of purified material. Table S3 . Thermodynamic parameters for the unfolding of synthetic proteins 1-9 and expressed proteins WT and K31A. a Protein ΔH° (kcal mol -1 )
TΔS° (kcal mol -1 )
Materials and Methods General Information. Solvents and all other reagents were purchased from Aldrich, Baker, EMD, or Fisher and used without further purification. HOBt was purchased from Anaspec Inc. HCTU, NovaPEG Rink Amide Resin, and Fmoc-protected α-amino acids were purchased from Novabiochem. Fmocprotected β 3 -amino acids were purchased from Aapptec. Column chromatography was performed using Silicycle SiliaFlash P60 (230-400 mesh) silica gel. Optical rotations were measured on a Perkin-Elmer 241 digital polarimeter with a sodium lamp at ambient temperature. NMR spectra were recorded on a Bruker Advance 400 spectrometer. Fmoc-β 2 -Ala-OH and Fmoc-β 2 -Lys(Boc) 2 -OH were synthesized according to published routes. 2 Fmoc-C α -Me-Val-OH was purchased from Aspira. Fmoc-C α -Me-Lys(Boc)-OH was purchased from W & J Pharma Chem Inc. Scheme S1. Synthesis of Fmoc-β 2 -Asn(Dmcp)-OH (S6) Ethyl (1S, 5R)-2-oxo-3-oxabicyclo [3.1.0] hexane-1-carboxylate (S1): Compound S1 was synthesized according to a published protocol. 3 Sodium (1.15 g, 50 mmol) was dissolved in ethanol (115 mL) under a N 2 atmosphere. The solution was cooled in an ice bath and diethyl malonate (9.2 mL, 60 mmol) was slowly added. After 10 minutes, R-epichlorohydrin (4.0 mL, 50 mmol) was slowly added over 20 minutes. The solution was refluxed overnight and concentrated. The residue was dissolved in water (100 mL) and the aqueous solution was extracted three times with 100 mL DCM. The organic layers were combined, dried with magnesium sulfate and concentrated. The concentrate was purified using column chromatography (20 % ethyl acetate in hexanes) to afford the product as a colorless oil (4.4 g, 26 mmol, 52 % yield). NMR data agreed with previously reported results. 3
Ethyl (3S,4S)-4-(azidomethyl)-2-oxotetrahydrofuran-3-carboxylate (S2): Compound S2
was synthesized according to a published protocol. 3 A solution of S1 (4.4 g, 26 mmol), sodium azide (6.7 g, 104 mmol), glacial acetic acid (5.9 mL, 104 mmol), and triethylamine (72 µL, 0.5 mmol) in anhydrous DMF (100 mL) was heated at 70 °C for 4 h under a N 2 atmosphere. The DMF was removed under reduced pressure and 200 mL saturated ammonium chloride solution was added. The aqueous solution was extracted three times with 200 mL DCM. The organic layers were washed three times with 100 mL saturated ammonium chloride, dried with magnesium sulfate, and concentrated to give the product as a colorless oil (3.9 g, 18.4 mmol, 71 % yield). NMR data agreed with previously published results. 3 (S)-4-(azidomethyl) dihydrofuran-2(3H)-one (S3): Compound S3 was synthesized according to a published protocol. 4 A solution of S2 (3.9 g, 18.4 mmol) and ptoluenesulfonic acid monohydrate (14.0 g, 74 mmol) in DMSO was heated at 120 °C overnight. The reaction was cooled, and 200 mL water was added. The solution was extracted four times with 200 mL ethyl acetate. The organic layers were washed three times with 100 mL saturated ammonium chloride, dried with magnesium sulfate, and concentrated to give the product as a colorless oil (1.5 g, 10.6 mmol, 57 % yield). NMR data agreed with previously published results. 4
(S)-4-azido-N-(2-cyclopropylpropan-2-yl)-3-(hydroxymethyl) butanamide (S4):
To a solution of aluminum chloride (3.1 g, 23.3 mmol) suspended in anhydrous DCM (100 mL) cooled on ice under a N 2 atmosphere was added triethylamine (6.5 mL, 47 mmol). The solution was stirred for 15 minutes before S3 (1.5 g, 10.6 mmol) and α,αdimethyl-cyclopropylmethanamine p-toluenesulfonic acid (3.2 g, 11.7 mmol) were added. The solution was stirred overnight at ambient temperature and concentrated. The residue was dissolved in 200 mL ethyl acetate and washed twice with 100 mL 5% sodium bicarbonate solution, once with 100 mL saturated ammonium chloride, and once with 100 mL brine. The organic layers were dried with magnesium sulfate and concentrated to afford the product as a colorless oil (1.6 g, 6.7 mmol, 63 % yield). Protein Synthesis. Synthesis and purification of proteins 1, 2, and 6 has been described previously. 1, 5 Proteins 3-5 were synthesized at room temperature (Method 1), while 7-9 were prepared by a combination of room temperature and microwave-assisted reactions (Method 2). All syntheses were carried out on a 70 µmol scale using NovaPEG Rink Amide resin. Method 1. Room temperature reactions were performed on a PTI Tribute automated synthesizer. In a standard coupling reaction, 2.5 mL of a solution composed of 0.2 M HCTU, 0.4 M N-methylmorpholine in DMF was added to 7 equivalents of Fmoc-amino acid relative to resin. After a 2 minute pre-activation, the solution was added to the resin and vortexed for 45 minutes. Deprotections were performed by two treatments with 3 mL of 20% v/v 4-methylpiperidine in DMF for 4 minutes each. The resin was washed four times with 3 mL of DMF after each coupling and deprotection step. After the final Fmoc deprotection, the resin was rinsed three times with 3 mL each DMF, DCM, and MeOH. The resin was dried in a vacuum desiccator for 20 minutes prior to TFA cleavage.
Method 2. Microwave reactions were performed using a CEM Microwave-Assisted Reaction System (MARS). Coupling cycles consisted of a 1.5 minute ramp to 90°C followed by a 2 minute hold, while deprotection cycles consisted of a 1.5 minute ramp to 90°C followed by a 1 minute hold. 6 Coupling solutions included protected amino acid (7 equiv), HATU (6.9 equiv), and DIEA (10.5 equiv) in DMF, and were preactivated for 2 minutes prior to addition to resin. Fmoc deprotections made use of 20% v/v 4methylpiperidine in DMF.
Unless otherwise indicated, synthesis was carried out by Method 1. Following are the modifications to the standard automated method made for specific proteins. For proteins 3-5 and 7-9, Glu 56 was doublecoupled, and pseudoproline dipeptides were used for residues Ala 48 Thr 49 and Glu 15 Thr 16 . Pseudoproline dipeptides were coupled with PyAOP or HATU for 90 minutes at room temperature. For protein 7, Aib residues were coupled with PyAOP for 90 minutes and the Ala residues immediately following each were double-coupled with PyAOP for 90 minutes each. For protein 8, αMeVal residues were coupled with HATU for 90 minutes, and the resin was capped with DMF/DIEA/Ac 2 O (8/2/1, v/v/v) for 10 minutes prior to deprotection. The Ala residues following each were double-coupled in the microwave (Method 2), with capping. For protein 9, Aib 35 was coupled with HATU for 90 minutes. Ala 34 was double-coupled with HATU for 90 minutes each, followed by capping. For residues 23-31, synthesis proceeded in the microwave (Method 2). Residues Phe 30 , Glu 27 and Ala 23 were double-coupled. Capping was done after αMeLys 31 , Phe 30 , αMeLys 28 , Glu 27 , and Ala 23 .
All proteins were cleaved from the resin in a cocktail of TFA/H 2 O/EDT/TIS (92.5/3/3/1.5 by volume) for approximately 3.5 hours on a rocker. Crude protein was precipitated from the TFA solution by addition of cold Et 2 O, and the mixture was centrifuged and decanted. The crude pellet was suspended in ~7 mL of 6M guanidinium, 0.025 M phosphate pH 7. The organic and aqueous layers of the resulting suspension were separated by centrifuge prior to purification.
Protein Expression. Proteins (WT and K31A) were expressed in E. coli following published protocols 7 using plasmids graciously provided by Timothy F. Cunningham and Sunil Saxena (University of Pittsburgh).
Protein Purification. All proteins were purified by preparative (300 Å pores, 10 µm beads) C18 reversephase HPLC using gradients composed of 0.1% TFA in water/acetonitrile. Protein identities were confirmed using mass spectrometry on a Voyager DE Pro MALDI-TOF instrument (Table S1 ). Following HPLC, proteins were further purified by anion-exchange chromatography on a MonoQ 5/50GL column (GE Healthcare) using 0.02 M Tris pH 8 buffer eluted with increasing concentrations of NaCl. Following ion-exchange, protein 9 was further purified using semi-preparative (300 Å pores, 5 µm beads) C18 reverse-phase HPLC using gradients as described above. Final purity of each protein was ≥95% by analytical RP-HPLC ( Figures S1-S3 ).
Circular Dichroism Spectroscopy. Circular dichroism measurements and data analysis were performed as described previously. 1 Concentration for all proteins was 40 µM except for protein 9 which was 8 µM due to poor synthetic yield.
Crystallography. Crystals were grown using the hanging drop vapor diffusion method. Stock solutions (18 mg/mL for 3, 20 mg/mL for 4 and 7) were mixed (0.7 µL + 0.7 µL) with crystallization buffer (Table  S2 ) and allowed to equilibrate at room temperature over a well of that buffer. Harvested crystals were cryoprotected with 30% v/v glycerol in the mother liquor then flash frozen in liquid nitrogen. X-ray diffraction data were collected using Cu/K α radiation on a Rigaku/MSC diffractometer (FR-E generator, VariMax optics) with a Saturn 944 CCD detector for 3 and 7 or a RAXIS HTC image plate detector for 4. Crystals were maintained at 100 K during diffraction experiments with an X-Stream 2000 lowtemperature system. Raw diffraction data were processed with d*TREK. Structures were solved by molecular replacement with a published structure of the expressed wild-type GB1 (PDB 4QMT) as a search model. Model refinement was performed with Phenix, 8 and manual real-space model building was accomplished using Coot. 9 Final data collection and refinement statistics may be found in Table S2 . Protein 4 exhibited signs of twinning as determined by Xtriage in Phenix, and the final structure was refined with a twin fraction of 0.27 and twin law of (H, -L, -K). Final coordinates and reflection files have been deposited in the PDB under accession codes 5HFY (protein 3), 5HG2 (protein 4), and 5HI1 (protein 7).
